Headland Capital’s Altimmune ALT Stock Holding History

Headland Capital’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,097	Closed	-$50.5K	–	58
2025 Q1	$50.5K	Buy	+10,097	New	+$64K	0.02%	59

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Headland Capital's ALT Position: Q2 2025 in Review

Headland Capital sold out of Altimmune (ALT) in Q2 2025, closing a stake of 10,097 shares — an estimated $50.5K sold.

Headland Capital first reported a position in ALT in Q1 2025 and held it in 1 quarter. The position peaked at $50.5K in Q1 2025. 180 funds tracked by Wall St. Rank hold ALT as of Q2 2025.

Headland Capital reported no remaining Altimmune position as of Q2 2025 after selling out during the quarter.
Headland Capital sold 10,097 Altimmune shares in Q2 2025, an estimated $50.5K.
Headland Capital first reported a position in Altimmune in Q1 2025 and held it in 1 quarter.
Headland Capital's Altimmune position peaked at $50.5K in Q1 2025.
180 funds tracked by Wall St. Rank held Altimmune as of Q2 2025.

Based on Headland Capital's 13F filing for Q2 2025, filed 22 Jul 2025.